This is an open-label, multicenter study designed to evaluate the efficacy and safety of
efalizumab administered at weekly SC (subcutaneous) doses of 1. 0 mg/kg followed by
efalizumab taper in subjects with plaque psoriasis who previously participated in Study
ACD2390g.
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Inclusion Criteria:
- Signed informed consent
- Previous participation in Study ACD2390g
- For women of childbearing potential, continued use of an acceptable method of
contraception for the duration of their participation in the study
- Willingness to continue to hold sun exposure reasonably constant and to avoid use of
tanning booths or other UV light sources throughout the study
Exclusion Criteria:
- Any medical condition that, in the judgment of the investigator, would jeopardize the
subject's safety following exposure to efalizumab
- Systemic therapy for psoriasis (ET Day 0 through FU Day 84 or upon relapse or unusual
presentation of psoriasis in the FU period, whichever occurs first)
- Systemic immunosuppressive drugs for other indications (ET Day 0 through FU Day 84)
- Topical therapies for psoriasis (ET Day 0 through ET Day 84)
- Live virus or bacteria vaccines (ET Day 0 through FU Day 84)
- Other vaccines or allergy desensitization (it is recommended that these be scheduled
after FU Day 84)
- Other experimental drugs or treatments (ET Day 0 through FU Day 84)
- Beta-Blockers, ACE inhibitors, interferons, quinidine, antimalarial drugs, or lithium
(if clinically indicated, such medications are allowed but the dosage should be held
constant between ET Day 0 and TT Day 84)